Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 8/2012

01-08-2012 | Review

Inflammatory markers and bariatric surgery: a meta-analysis

Author: S. Raghavendra Rao

Published in: Inflammation Research | Issue 8/2012

Login to get access

Abstract

Objective

Obesity is a state of chronic low grade inflammation with increased levels of inflammatory markers such as C-reactive protein (CRP), interleukin (IL)-6 and tumor necrosis factor (TNF) α. The changes of some of the above markers after bariatric surgery are not consistent across studies. The objective of this study is to confirm the changes in blood levels of CRP, IL-6 and TNFα after bariatric surgery.

Methods

A Pubmed and EMBASE search was performed for studies measuring the above cytokines in blood before and after bariatric surgery. A meta-analysis was performed for the changes in CRP, TNFα and IL-6 for the maximum follow-up time in each study as well as for discrete follow-up times.

Results

Only observational studies could be retrieved. Bariatric surgery produces about 66 and 27 % reduction in CRP and IL-6 levels, respectively. The change in TNFα after bariatric surgery did not approach statistical significance.

Conclusion

Bariatric surgery decreases the low grade inflammation associated with obesity as measured by CRP and IL-6 levels. The change of TNFα after bariatric surgery should be further investigated with randomized trials.
Literature
1.
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283:2008–12.PubMedCrossRef
2.
Pardina E, Ferrer R, Baena-Fustegueras JA, Rivero J, Lecube A, Fort JM, Vargas V, Catalan R, Peinado-Onsurbe J. Only C-reactive protein, but not TNF-alpha or IL6, reflects the improvement in inflammation after bariatric surgery. Obes Surg. 2012;22:131–9.PubMedCrossRef
3.
Huang H, Kasumov T, Gatmaitan P, Heneghan HM, Kashyap SR, Schauer PR, Brethauer SA, Kirwan JP. Gastric bypass surgery reduces plasma ceramide subspecies and improves insulin sensitivity in severely obese patients. Obesity (Silver Spring). 2011;19:2235–40.CrossRef
4.
Komorowski J, Jankiewicz-Wika J, Kolomecki K, Cywinski J, Piestrzeniewicz K, Swietoslawski J, Stepien H. Systemic blood osteopontin, endostatin, and E-selectin concentrations after vertical banding surgery in severely obese adults. Cytokine. 2011;55:56–61.PubMedCrossRef
5.
Miller GD, Nicklas BJ, Fernandez A. Serial changes in inflammatory biomarkers after Roux-en-Y gastric bypass surgery. Surg Obes Relat Dis. 2011;7:618–24.PubMedCrossRef
6.
Pallayova M, Steele KE, Magnuson TH, Schweitzer MA, Smith PL, Patil SP, Bevans-Fonti S, Polotsky VY, Schwartz AR. Sleep apnea determines soluble TNF-alpha receptor 2 response to massive weight loss. Obes Surg. 2011;21:1413–23.PubMedCrossRef
7.
de Luis DA, Pacheco D, Aller R. Influence of G308A polymorphism of tumor necrosis factor alpha gene on surgical results of biliopancreatic diversion. Obes Surg. 2010;20:221–5.PubMedCrossRef
8.
Tussing-Humphreys L, Pini M, Ponemone V, Braunschweig C, Fantuzzi G. Suppressed cytokine production in whole blood cultures may be related to iron status and hepcidin and is partially corrected following weight reduction in morbidly obese pre-menopausal women. Cytokine. 2011;53:201–6.PubMedCrossRef
9.
Kopp HP, Krzyzanowska K, Schernthaner GH, Kriwanek S, Schernthaner G. Relationship of androgens to insulin resistance and chronic inflammation in morbidly obese premenopausal women: studies before and after vertical banded gastroplasty. Obes Surg. 2006;16:1214–20.PubMedCrossRef
10.
Bueter M, Dubb SS, Gill A, Joannou L, Ahmed A, Frankel AH, Tam FW, le Roux CW. Renal cytokines improve early after bariatric surgery. Br J Surg. 2010;97:1838–44.PubMedCrossRef
11.
Vazquez LA, Pazos F, Berrazueta JR, Fernandez-Escalante C, Garcia-Unzueta MT, Freijanes J, Amado JA. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab. 2005;90:316–22.PubMedCrossRef
12.
Tussing-Humphreys LM, Nemeth E, Fantuzzi G, Freels S, Holterman AX, Galvani C, Ayloo S, Vitello J, Braunschweig C. Decreased serum hepcidin and improved functional iron status 6 months after restrictive bariatric surgery. Obesity (Silver Spring). 2010;18:2010–6.CrossRef
13.
Maruna P, Gurlich R, Fried M, Frasko R, Chachkhiani I, Haluzik M. Leptin as an acute phase reactant after non-adjustable laparoscopic gastric banding. Obes Surg. 2001;11:609–14.PubMedCrossRef
14.
Tschoner A, Sturm W, Ress C, Engl J, Kaser S, Laimer M, Laimer E, Klaus A, Tilg H, Patsch JR, Ebenbichler CF. Effect of weight loss on serum pigment epithelium-derived factor levels. Eur J Clin Invest. 2011;41:937–42.PubMedCrossRef
15.
Sainsbury A, Goodlad RA, Perry SL, Pollard SG, Robins GG, Hull MA. Increased colorectal epithelial cell proliferation and crypt fission associated with obesity and roux-en-Y gastric bypass. Cancer Epidemiol Biomarkers Prev. 2008;17:1401–10.PubMedCrossRef
16.
van de Sande-Lee S, Pereira FR, Cintra DE, Fernandes PT, Cardoso AR, Garlipp CR, Chaim EA, Pareja JC, Geloneze B, Li LM, Cendes F, Velloso LA. Partial reversibility of hypothalamic dysfunction and changes in brain activity after body mass reduction in obese subjects. Diabetes. 2011;60:1699–704.PubMedCrossRef
17.
Ress C, Tschoner A, Engl J, Klaus A, Tilg H, Ebenbichler CF, Patsch JR, Kaser S. Effect of bariatric surgery on circulating chemerin levels. Eur J Clin Invest. 2010;40:277–80.PubMedCrossRef
18.
Perez-Romero N, Serra A, Granada ML, Rull M, Alastrue A, Navarro-Diaz M, Romero R, Fernandez-Llamazares J. Effects of two variants of Roux-en-Y Gastric bypass on metabolism behaviour: focus on plasma ghrelin concentrations over a 2-year follow-up. Obes Surg. 2010;20:600–9.PubMedCrossRef
19.
Hakeam HA, O’Regan PJ, Salem AM, Bamehriz FY, Eldali AM. Impact of laparoscopic sleeve gastrectomy on iron indices: 1 year follow-up. Obes Surg. 2009a;19:1491–6.PubMedCrossRef
20.
Agrawal V, Krause KR, Chengelis DL, Zalesin KC, Rocher LL, McCullough PA. Relation between degree of weight loss after bariatric surgery and reduction in albuminuria and C-reactive protein. Surg Obes Relat Dis. 2009;5:20–6.PubMedCrossRef
21.
Hakeam HA, O’Regan PJ, Salem AM, Bamehriz FY, Jomaa LF. Inhibition of C-reactive protein in morbidly obese patients after laparoscopic sleeve gastrectomy. Obes Surg. 2009b;19:456–60.PubMedCrossRef
22.
Manco M, Fernandez-Real JM, Equitani F, Vendrell J. Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. J Clin Endocrinol Metab. 2007;92:483–90.PubMedCrossRef
23.
Chen SB, Lee YC, Ser KH, Chen JC, Chen SC, Hsieh HF, Lee WJ. Serum C-reactive protein and white blood cell count in morbidly obese surgical patients. Obes Surg. 2009;19:461–6.PubMedCrossRef
24.
Gannage-Yared MH, Yaghi C, Habre B, Khalife S, Noun R, Germanos-Haddad M, Trak-Smayra V. Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study. Eur J Endocrinol. 2008;158:353–9.PubMedCrossRef
25.
Lin E, Phillips LS, Ziegler TR, Schmotzer B, Wu K, Gu LH, Khaitan L, Lynch SA, Torres WE, Smith CD, Gletsu-Miller N. Increases in adiponectin predict improved liver, but not peripheral, insulin sensitivity in severely obese women during weight loss. Diabetes. 2007a;56:735–42.PubMedCrossRef
26.
Lin LY, Lee WJ, Shen HN, Yang WS, Pai NH, Su TC, Liau CS. Nitric oxide production is paradoxically decreased after weight reduction surgery in morbid obesity patients. Atherosclerosis. 2007b;190:436–42.PubMedCrossRef
27.
Geloneze SR, Geloneze B, Morari J, Matos-Souza JR, Lima MM, Chaim EA, Pareja JC, Velloso LA. PGC1alpha gene Gly482Ser polymorphism predicts improved metabolic, inflammatory and vascular outcomes following bariatric surgery. Int J Obes (Lond). 2012;36:363–8.CrossRef
28.
De Ciuceis C, Porteri E, La Boria E, Boari G, Mittempergher F, Di Betta E, Casella C. Subcutaneous small resistance artery morphology and circulating indices of inflammation/oxidative stress in obese patients before and after bariatric surgery and consistent weight loss. High Blood Press Cardiovasc Prev. 2011;18:158.
29.
Melendez Araujo M, De Matos Arruda S, Silva Oliveira M, Franca F, Barros R, Medeiros Santos R, Cubas Rolim E, Daher Milhomem P, Ferreira Neves C. Evaluation of inflamatory and metabolic state of patients with steatosis before Roux-en-Y gastric bypass procedure and after six months of operation. Obes Surg. 2011;21:1129.
30.
Di Renzo L, Carbonelli MG, Bianchi A, Iacopino L, Fiorito R, Di Daniele N, De Lorenzo A. Body composition changes after laparoscopic adjustable gastric banding: what is the role of -174G>C interleukin-6 promoter gene polymorphism in the therapeutic strategy? Int J Obes (Lond). 2012;36:369–78.CrossRef
31.
Wolf T, Rauschmayer M, Dressler M, Ring A, Britz A, Lohmann T. Changes of hormone levels in the early period after bariatric surgery. Obes Surg. 2011;21:1079.
32.
Fica S, Sirbu A, Copaescu C, Olaru R, Florea S. Significant improvement in metabolic status 6 months after bariatric surgery. Diabetes Technol Ther. 2011;13:223–4.
33.
Wong A, Chan D, Armstrong J, Watts G. Effect of laparoscopic sleeve gastrectomy on elevated C-reactive protein and atherogenic dyslipidemia in morbidly obese patients. Clin Biochem. 2011;44:342–4.PubMedCrossRef
34.
Faria G, Preto J, Gouveia A, Barbosa J, Carneiro S, Costa E, Teixeira C, Gil C, Sousa-Rodrigues J, Alves J. Decrease in inflammatory state and insulin-resistance 6 to 12 months after laparoscopic Roux-en-Y gastric bypass (LRYGB). Obes Surg. 2010;20:1056.CrossRef
35.
Komorowski J, Jankiewicz-Wika J, Kolomecki K, Cywinski J, Piestrzeniewicz K. Peripheral blood concentrations of adipocytokines, inflammation and metabolic syndrome markers after bariatric surgery. Obes Rev. 2010;11:251.CrossRef
36.
Boesing F, Moreira E, Wilhelm-Filho D, Vigil S, Parizottto E, Inacio D, Portari G, Trindade E, Jordao-Junior A, Frode T. Roux-en-Y bypass gastroplasty: markers of oxidative stress 6 months after surgery. Obes Surg. 2010;20:1236–44.PubMedCrossRef
37.
Richette P, Poitou C, Garnero P, Vicaut E, Bouillot JL, Lacorte JM, Basdevant A, Clement K, Bardin T, Chevalier X. Benefits of massive weight loss on symptoms, systemic inflammation and cartilage turnover in obese patients with knee osteoarthritis. Ann Rheum Dis. 2011;70:139–44.PubMedCrossRef
38.
Lima MM, Pareja JC, Alegre SM, Geloneze SR, Kahn SE, Astiarraga BD, Chaim EA, Geloneze B. Acute effect of roux-en-y gastric bypass on whole-body insulin sensitivity: a study with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95:3871–5.PubMedCrossRef
39.
Woodard G, Peraza J, Bravo S, Toplosky L, Hernandez-Boussard T, Morton J. One year improvements in cardiovascular risk factors: A comparative trial of laparoscopic Roux-en-Y gastric bypass vs. adjustable gastric banding. Obes Surg. 2010;20:578–82.PubMedCrossRef
40.
Swarbrick MM, Stanhope KL, Austrheim-Smith IT, Van Loan MD, Ali MR, Wolfe BM, Havel PJ. Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery. Diabetologia. 2008;51:1901–11.PubMedCrossRef
41.
Malheiros C, Freitas W, Saleh M, Taha M, Bertolami M. Bariatric surgery decreases the inflammatory response in the 6 months post-operatory. Obes Surg. 2009;19:1013.
42.
Carroll J, Franks S, Smith A, Phelps D. Visceral adipose tissue loss and insulin resistance 6 months after laparoscopic gastric banding surgery: A preliminary study. Obes Surg. 2009;19:47–55.PubMedCrossRef
43.
Chacon MR, Miranda M, Jensen CH, Fernandez-Real JM, Vilarrasa N, Gutierrez C, Naf S, Gomez JM, Vendrell J. Human serum levels of fetal antigen 1 (FA1/Dlk1) increase with obesity, are negatively associated with insulin sensitivity and modulate inflammation in vitro. Int J Obes (Lond). 2008;32:1122–9.CrossRef
44.
Zagorski S, Papa N, Chung M. The effect of weight loss after gastric bypass on C-reactive protein levels. Surg Obes Relat Dis. 2005;1:81–5.PubMedCrossRef
45.
Broch M, Gomez JM, Auguet MT, Vilarrasa N, Pastor R, Elio I, Olona M, Garcia-Espana A, Richart C. Association of retinol-binding protein-4 (RBP4) with lipid parameters in obese women. Obes Surg. 2010;20:1258–64.PubMedCrossRef
46.
Schaller G, Aso Y, Schernthaner GH, Kopp HP, Inukai T, Kriwanek S, Schernthaner G. Increase of osteopontin plasma concentrations after bariatric surgery independent from inflammation and insulin resistance. Obes Surg. 2009;19:351–6.PubMedCrossRef
47.
Botella-Carretero JI, Alvarez-Blasco F, Martinez-Garcia MA, Luque-Ramirez M. The decrease in serum IL-18 levels after bariatric surgery in morbidly obese women is a time-dependent event. Obes Surg. 2007;17:1199–208.PubMedCrossRef
48.
Moschen AR, Molnar C, Enrich B, Geiger S, Ebenbichler CF, Tilg H. Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss. Mol Med. 2011;17:840–5.PubMedCrossRef
49.
Simon I, Escote X, Vilarrasa N, Gomez J, Fernandez-Real JM, Megia A, Gutierrez C, Gallart L, Masdevall C, Vendrell J. Adipocyte fatty acid-binding protein as a determinant of insulin sensitivity in morbid-obese women. Obesity (Silver Spring). 2009;17:1124–8.
50.
Fain JN. Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. Mediat Inflamm. 2010;2010:513948.CrossRef
51.
Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82(12):4196–200.PubMedCrossRef
52.
Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998;83:847–50.PubMedCrossRef
53.
Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Investig. 2006;116:3015–25.PubMedCrossRef
54.
Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Investig. 2003;112:1796–808.PubMed
55.
Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Investig. 2003;112:1821–30.PubMed
56.
Cancello R, Tordjman J, Poitou C, Guilhem G, Bouillot JL, Hugol D, et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes. 2006;55:1554–61.PubMedCrossRef
57.
Nieto-Vazquez I, Fernández-Veledo S, Krämer DK, Vila-Bedmar R, Garcia-Guerra L, Lorenzo M. Insulin resistance associated to obesity: the link TNF-alpha. Arch Physiol Biochem. 2008;114:183–94.PubMedCrossRef
58.
Hotamisligil GS. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes. 1999;107:119–25.PubMedCrossRef
59.
Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab. 2003;14:137–45.PubMedCrossRef
60.
Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK. Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes. 2005;54:2939–45.PubMedCrossRef
61.
Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, Llorca J. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006;24:83–6.PubMed
62.
Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes. 1996;45:881–5.PubMedCrossRef
63.
Seriolo BC, Ferrone, Cutolo M. Longterm anti-tumor necrosis factor-alpha treatment in patients with refractory rheumatoid arthritis: relationship between insulin resistance and disease activity. J Rheumatol. 2008;35(2):355–7.PubMed
64.
Tam LS, Tomlinson B, Chu TT, Li TK, Li EK. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol. 2007;26:1495–8.PubMedCrossRef
65.
Ferraz-Amaro I, Arce-Franco M, Muñiz J, López-Fernández J, Hernández-Hernández V, Franco A, Quevedo J, Martínez-Martín J, Díaz-González F. Systemic blockade of TNF-alpha does not improve insulin resistance in humans. Horm Metab Res. 2011;43:801–8.PubMedCrossRef
66.
Schreyer SA, Chua SC Jr, LeBoeuf RC. Obesity and diabetes in TNF-alpha receptor-deficient mice. J Clin Investig. 1998;102:402–11.PubMedCrossRef
67.
Uysal KT, Wiesbrock SM, Hotamisligil GS. Functional analysis of tumor necrosis factor (TNF) receptors in TNF-alpha-mediated insulin resistance in genetic obesity. Endocrinology. 1998;139:4832–8.PubMedCrossRef
68.
69.
Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82:4196–200.PubMedCrossRef
70.
71.
Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med. 2002;8:75–9.CrossRef
72.
Di Gregorio GB, Hensley L, Lu T, Ranganathan G, Kern PA. Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. Am J Physiol Endocrinol Metab. 2004;287:E182–7.PubMedCrossRef
73.
Inoue H, Ogawa W, Asakawa A, Okamoto Y, Nishizawa A, Matsumoto M, Teshigawara K, Matsuki Y, Watanabe E, Hiramatsu R, Notohara K, Katayose K, Okamura H, Kahn CR, Noda T, Takeda K, Akira S, Inui A, Kasuga M. Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab. 2006;3:267–75.PubMedCrossRef
74.
Klover PJ, Clementi AH, Mooney RA. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology. 2005;146:3417–27.PubMedCrossRef
75.
Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes. 2003;52:2784–9.PubMedCrossRef
76.
Carey AL, Febbraio MA. Interleukin-6 and insulin sensitivity: friend or foe? Diabetologia. 2004;47:1135–42.PubMed
77.
Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, Prelovsek O, Hohnen-Behrens C, Watt MJ, James DE, Kemp BE, Pedersen BK, Febbraio MA. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes. 2006;55:2688–97.PubMedCrossRef
78.
Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun. 2003;311:372–9.PubMedCrossRef
79.
Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem. 2003;278:45777–84.PubMedCrossRef
80.
Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J, Paschke R. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2003;301:1045–50.PubMedCrossRef
81.
Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol. 2009;20:182–9.PubMedCrossRef
82.
Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes. 2007;56:1010–3.PubMedCrossRef
83.
Frolich M, Imhof A, Berg G, Hutchinson W, Pepys M, Boeing H, et al. Association between C-reactive protein and features of the metabolic syndrome: a population based study. Diabetes Care. 2000;23:1835–9.CrossRef
84.
Majello B, Arcone R, Toniatti C, Ciliberto G. Constitutive and IL-6-induced nuclear factors that interact with the human C-reactive protein promoter. EMBO J. 1990;9:457–65.PubMed
85.
Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131–5.PubMedCrossRef
86.
Faber DR, van der Graaf Y, Westerink J, Visseren FL. Increased visceral adipose tissue mass is associated with increased C-reactive protein in patients with manifest vascular diseases. Atherosclerosis. 2010;212:274–80.PubMedCrossRef
87.
Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome. Diabetologia. 1997;40:1286–92.PubMedCrossRef
88.
Faber DR, van der Graaf Y, Westerink J, Visseren FL. A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. Am J Med. 2004;117:398–405.CrossRef
89.
Howard BV, Best L, Comuzzie A, Ebbesson SO, Epstein SE, Fabsitz RR, Howard WJ, Silverman A, Wang H, Zhu J, Umans J. C-reactive protein, insulin resistance, and metabolic syndrome in a population with a high burden of subclinical infection: insights from the genetics of coronary artery disease in Alaska natives (GOCADAN) study. Diabetes Care. 2008;31:2312–4.PubMedCrossRef
90.
Tsuriya D, Morita H, Morioka T, Takahashi N, Ito T, Oki Y, Nakamura H. Significant correlation between visceral adiposity and high-sensitivity C-reactive protein (hs-CRP) in Japanese subjects. Intern Med. 2011;50:2767–73.PubMedCrossRef
91.
Xi L, Xiao C, Bandsma RH, Naples M, Adeli K, Lewis GF. C-reactive protein impairs hepatic insulin sensitivity and insulin signaling in rats: role of mitogen-activated protein kinases. Hepatology. 2011;53:127–35.PubMedCrossRef
92.
Chieko Mineo, Longoria C, Vongpatanasin W, Shaul PW Abstract 5550: C-reactive protein (CRP) causes insulin resistance in mice through FcRIIB-mediated inhibition of insulin signaling circulation. 2009; 120: S1114.
93.
Muller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B, et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia. 2002;45:805–12.PubMedCrossRef
94.
Holdstock C, Lind L, Engstrom BE, Ohrvall M, Sundbom M, Larsson A, et al. CRP reduction following gastric bypass surgery is most pronounced in insulin-sensitive subjects. Int J Obes (Lond). 2005;29:1275–80.CrossRef
95.
Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:4649–54.PubMedCrossRef
96.
Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol. 2003;42:1757–63.PubMedCrossRef
97.
van Dielen FM, van’t Veer C, Schols AM, Soeters PB, Buurman WA, Greve JW. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obes Relat Metab Disord. 2001;25:1759–66.PubMedCrossRef
98.
Chen K, Li F, Li J, Cai H, Strom S, Bisello A, Kelley DE, Friedman-Einat M, Skibinski GA, McCrory MA, Szalai AJ, Zhao AZ. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med. 2006;12:425–32.PubMedCrossRef
99.
Finck BN, Johnson RW. Tumor necrosis factor (TNF)-alpha induces leptin production through the p55 TNF receptor. Am J Physiol Regul Integr Comp Physiol. 2000;278:R537–43.PubMed
100.
Zhao T, Hou M, Xia M, Wang Q, Zhu H, Xiao Y, Tang Z, Ma J, Ling W. Globular adiponectin decreases leptin-induced tumor necrosis factor-alpha expression by murine macrophages: involvement of cAMP-PKA and MAPK pathways. Cell Immunol. 2005;238:19–30.PubMedCrossRef
101.
Tang CH, Lu DY, Yang RS, Tsai HY, Kao MC, Fu WM, Chen YF. Leptin-induced IL-6 production is mediated by leptin receptor, insulin receptor substrate-1, phosphatidylinositol 3-kinase, Akt, NF-kappaB, and p300 pathway in microglia. J Immunol. 2007;179:1292–302.PubMed
102.
Park PH, McMullen MR, Huang H, Thakur V, Nagy LE. Short-term treatment of RAW264.7 macrophages with adiponectin increases tumor necrosis factor-alpha (TNF-alpha) expression via ERK1/2 activation and Egr-1 expression: role of TNF-alpha in adiponectin-stimulated interleukin-10 production. J Biol Chem. 2007;282:21695–703.PubMedCrossRef
103.
Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003;107:671–4.PubMedCrossRef
104.
Olszanecka-Glinianowicz M, Kocełak P, Janowska J, Skorupa A, Nylec M, Zahorska-Markiewicz B. Plasma visfatin and tumor necrosis factor-alpha (TNF-alpha) levels in metabolic syndrome. Kardiol Pol. 2011;69:802–7.PubMed
105.
Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426–30.PubMedCrossRef
106.
Li H, Liu P, Cepeda J, Fang D, Easley RB, Simon BA, Zhang LQ, Ye SQ. Augmentation of pulmonary epithelial cell IL-8 expression and permeability by pre-B-cell colony enhancing factor. J Inflamm (Lond). 2008;5:15.CrossRef
107.
Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 2007;178:1748–58.PubMed
108.
Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M, et al. Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab. 2005;289:E586–90.PubMedCrossRef
109.
Bastard JP, Jardel C, Bruckert E, Vidal H, Hainque B. Variations in plasma soluble tumour necrosis factor receptors after diet-induced weight loss in obesity. Diabetes Obes Metab. 2000;2:323–5.PubMedCrossRef
110.
Heilbronn LK, Noakes M, Clifton PM. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol. 2001;21:968–70.PubMedCrossRef
111.
Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation. 2002;105:564–9.PubMedCrossRef
112.
Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab. 2000;85:3338–42.PubMedCrossRef
113.
Tsukui S, Kanda T, Nara M, Nishino M, Kondo T, Kobayashi I. Moderate intensity regular exercise decreases serum tumor necrosis factor-a and HbA1c levels in healthy women. Int J Obes Relat Metab Disord. 2000;24:1207–11.PubMedCrossRef
114.
Straczkowski M, Kowalska I, Dzienis-Straczkowska S, Stepién A, Skibińska E, Szelachowska M, et al. Changes in tumor necrosis factor-a system and insulin sensitivity during an exercise training program in obese women with normal and impaired glucose tolerance. Eur J Endocrinol. 2001;145:273–80.PubMedCrossRef
115.
Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes. 2006;54:2277–86.CrossRef
116.
Zhang H, Wang Y, Zhang J, Potter BJ, Sowers JR, Zhang C. Bariatric surgery reduces visceral adipose inflammation and improves endothelial function in type 2 diabetic mice. Arterioscler Thromb Vasc Biol. 2011;31:2063–9.PubMedCrossRef
117.
Greco AV, Mingrone G, Giancaterini A, Manco M, Morroni M, Cinti S, Granzotto M, Vettor R, Camastra S, Ferrannini E. Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes. 2002;51:144–51.PubMedCrossRef
118.
Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Körfer R, Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. 2003;41:105–12.PubMedCrossRef
119.
Bellia A, Garcovich C, D’Adamo M, Lombardo M, Tesauro M, Donadel G et al. Serum 25-hydroxyvitamin D levels are inversely associated with systemic inflammation in severe obese subjects. Intern Emerg Med. 2011 Epub.
Metadata
Title
Inflammatory markers and bariatric surgery: a meta-analysis
Author
S. Raghavendra Rao
Publication date
01-08-2012
Publisher
SP Birkhäuser Verlag Basel
Published in
Inflammation Research / Issue 8/2012
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-012-0473-3

Other articles of this Issue 8/2012

Inflammation Research 8/2012 Go to the issue

Original Research Paper

Association of promoter region single nucleotide polymorphisms at positions −819C/T and −592C/A of interleukin 10 gene with ischemic heart disease

Original Research Paper

Anti-inflammatory effects of arbutin in lipopolysaccharide-stimulated BV2 microglial cells

Original Research Paper

Chronic aspiration shifts the immune response from adaptive immunity to innate immunity in a murine model of asthma

Original Research Paper

Use of blood urea nitrogen, creatinine, interleukin-6, granulocyte–macrophage colony stimulating factor in combination to predict the severity and outcome of abdominal sepsis in rats

Original Research Paper

8-Isoprostane, prostaglandin E2, C-reactive protein and serum amyloid A as markers of inflammation and oxidative stress in antiphospholipid syndrome: a pilot study

Original Research Paper

Pretreatment with anti-flagellin serum delays acute lung injury in rats with sepsis

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits